Therapeutic cancer vaccines and translating vaccinomics science to the global health clinic: Emerging applications toward proof of concept

OMICS A Journal of Integrative Biology

Volumn 15, Issue 9, 2011, Pages 579-588

  O'Meara, Megan M ^a   Disis, Mary L ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CANCER VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NY ESO 1 ANTIGEN; SOMATOMEDIN B; TUMOR ANTIGEN;

BIOMICS; CANCER IMMUNOTHERAPY; HLA SYSTEM; HUMAN; IMMUNE RESPONSE; IMMUNOGENETICS; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN MICROARRAY; REVIEW; TUMOR IMMUNOLOGY; VACCINOMICS;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; GENE EXPRESSION PROFILING; GENOME-WIDE ASSOCIATION STUDY; GENOMICS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; NEOPLASMS; PHARMACOGENETICS; PROTEOMICS; WORLD HEALTH;

EID: 80052756245     PISSN: 15362310     EISSN: 15578100     Source Type: Journal    
DOI: 10.1089/omi.2010.0149     Document Type: Review

References (71)

1. Anderson, K.S., Ramachandran, N., Wong, J., Raphael, J.V., Hainsworth, E., Demirkan, G., et al. (2008). Application of protein microarrays for multiplexed detection of antibodies to tumor antigens in breast cancer. J Proteome Res 7, 1490-1499.
2. Biernacki, M.A., Marina, O., Zhang, W., Liu, F., Bruns, I., Cai, A., et al. (2010). Efficacious immune therapy in chronic myelogenous leukemia (CML) recognizes antigens that are expressed on CML progenitor cells. Cancer Res 70, 906-915.
3. Blixt, O., Clo, E., Nudelman, A.S., Sorensen, K.K., Clausen, T., Wandall, H.H., et al. (2010). A high-throughput O-glycopeptide discovery platform for seromic profiling. J Proteome Res 9, 5250-5261.
4. Bogunovic, D., O'Neill, D.W., Belitskaya-Levy, I., Vacic, V., Yu, Y.L., Adams, S., et al. (2009). Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc Natl Acad Sci USA 106, 20429-20434.
5. Brouard, S., Mansfield, E., Braud, C., Li, L., Giral, M., Hsieh, S.C., et al. (2007). Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance. Proc Natl Acad Sci USA 104, 15448-15453. (Pubitemid 47502937)
6. Butterfield, L.H., Ribas, A., Dissette, V.B., Amarnani, S.N., Vu, H.T., Oseguera, D., et al. (2003). Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res 9, 998-1008. (Pubitemid 36323703)
7. Casalegno-Garduno, R., Schmitt, A., Yao, J., Wang, X., Xu, X., Freund, M., et al. (2010). Multimer technologies for detection and adoptive transfer of antigen-specific T cells. Cancer Immunol Immunother 59, 195-202.
8. Chatterjee, M., Draghici, S., and Tainsky, M.A. (2006a). Immunotheranostics: breaking tolerance in immunotherapy using tumor autoantigens identified on protein microarrays. Curr Opin Drug Discov Dev 9, 380-385. (Pubitemid 43774166)
9. Chatterjee, M., Mohapatra, S., Ionan, A., Bawa, G., Ali-Fehmi, R., Wang, X., et al. (2006b). Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays. Cancer Res 66, 1181-1190. (Pubitemid 43165989)
10. Chen, Y.T., Scanlan, M.J., Sahin, U., Tureci, O., Gure, A.O., Tsang, S., et al. (1997). A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 94, 1914-1918. (Pubitemid 27113936)
11. Daar, A.S., Thorsteinsdottir, H., Martin, D.K., Smith, A.C., Nast, S., and Singer, P.A. (2002). Top ten biotechnologies for improving health in developing countries. Nat Genet 32, 229-232.
12. DeMichele, A., Martin, A.M., Mick, R., Gor, P., Wray, L., Klein- Cabral, M., et al. (2003). Interleukin-6-174G-C polymorphism is associated with improved outcome in high-risk breast cancer. Cancer Res 63, 8051-8056.
13. Disis, M.L. (2010). Immune regulation of cancer. J Clin Oncol 28, 4531-4538.
14. Disis, M.L. (2011). Immunologic biomarkers as correlates of clinical response to cancer immunotherapy. Cancer Immunol Immunother Jan 8 [Epub ahead of print].
15. Disis, M.L., Goodell, V., Schiffman, K., and Knutson, K.L. (2004). Humoral epitope-spreading following immunization with a HER-2/neu peptide based vaccine in cancer patients. J Clin Immunol 24, 571-578. (Pubitemid 39221675)
16. Disis, M.L., Wallace, D.R., Gooley, T.A., Dang, Y., Slota, M., Lu, H., et al. (2009). Concurrent trastuzumab and HER2/neuspecific vaccination in patients with metastatic breast cancer. J Clin Oncol 27, 4685-4692.
17. Emamian, E.S., Leon, J.M., Lessard, C.J., Grandits, M., Baechler, E.C., Gaffney, P.M., et al. (2009). Peripheral blood gene ex-pression profiling in Sjogren's syndrome. Genes Immun 10, 285-296.
18. Fong, L., Kwek, S.S., O'Brien, S., Kavanagh, B., McNeel, D.G., Weinberg , V., et al. (2009). Potentiating endogenous antitumorimmunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res 69, 609-615.
19. Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pages, C., et al. (2006). Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960-1964. (Pubitemid 44498003)
20. Garcia-Pineres, A.J., Hildesheim, A., Dodd, L., Kemp, T.J., Yang, J., Fullmer, B., et al. (2009). Gene expression patterns induced by HPV-16 L1 virus-like particles in leukocytes from vaccine recipients. J Immunol 182, 1706-1729.
21. Guan, P., Hattotuwagama, C.K., Doytchinova, I.A., and Flower, D.R. (2006). MHCPred 2.0: an updated quantitative T-cell epitope prediction server. Appl Bioinformatics 5, 55-61.
22. Gunawardana, C.G., and Diamandis, E.P. (2007). High throughput proteomic strategies for identifying tumour-associated antigens. Cancer Lett 249, 110-119. (Pubitemid 46428005)
23. Gunther, O.P., Balshaw, R.F., Scherer, A., Hollander, Z., Mui, A., Triche, T.J., et al. (2009). Functional genomic analysis of peripheral blood during early acute renal allograft rejection. Transplantation 88, 942-951.
24. Hardouin, J., Lasserre, J.P., Sylvius, L., Joubert-Caron, R., and Caron, M. (2007). Cancer immunomics: from serological proteome analysis to multiple affinity protein profiling. Ann N Y Acad Sci 1107, 223-230. (Pubitemid 47528799)
25. Julia, A., Erra, A., Palacio, C., Tomas, C., Sans, X., Barcelo, P., et al. (2009). An eight-gene blood expression profile predicts the response to infliximab in rheumatoid arthritis. PLoS One 4, e7556.
26. Kalli, K.R., Krco, C.J., Hartmann, L.C., Goodman, K., Maurer, M.J., Yu, C., et al. (2008). An HLA-DR-degenerate epitope pool detects insulin-like growth factor binding protein 2-specific immunity in patients with cancer. Cancer Res 68, 4893-4901.
27. Kantoff, P.W., Higano, C.S., Shore, N.D., Berger, E.R., Small, E.J., Penson, D.F., et al. (2010). Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363, 411-422.
28. Kessler, J.H., Beekman, N.J., Bres-Vloemans, S.A., Verdijk, P., van Veelen, P.A., Kloosterman-Joosten, A.M., et al. (2001). Efficient identification of novel HLA-A 0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J Exp Med 193, 73-88. (Pubitemid 32060699)
29. Kessler, J.H., and Melief, C.J. (2007). Identification of T-cell epitopes for cancer immunotherapy. Leukemia 21, 1859-1874. (Pubitemid 47299958)
30. Klade, C.S., Voss, T., Krystek, E., Ahorn, H., Zatloukal, K., Pummer, K., et al. (2001). Identification of tumor antigens in renal cell carcinoma by serological proteome analysis. Proteomics 1, 890-898. (Pubitemid 33587414)
31. Liu, M.A. (2011). DNA vaccines: an historical perspective and view to the future. Immunol Rev 239, 62-84.
32. Lu, H., Knutson, K.L., Gad, E., and Disis, M.L. (2006). The tumor antigen repertoire identified in tumor-bearing neu transgenic mice predicts human tumor antigens. Cancer Res 66, 9754-9761. (Pubitemid 44623677)
33. Lu, H., Goodell, V., and Disis, M.L. (2008). Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer. J Proteome Res 7, 1388-1394.
34. Lu, H., Wagner, W.M., Gad, E., Yang, Y., Duan, H., Amon, L.M., et al. (2010). Treatment failure of a TLR-7 agonist occurs due to self-regulation of acute inflammation and can be overcome by IL-10 blockade. J Immunol 184, 5360-5367.
35. Lu, J., and Celis, E. (2000). Use of two predictive algorithms of the world wide web for the identification of tumor-reactive Tcell epitopes. Cancer Res 60, 5223-5227.
36. Mandruzzato, S., Callegaro, A., Turcatel, G., Francescato, S., Montesco, M.C., Chiarion-Sileni, V., et al. (2006). A gene expression signature associated with survival in metastatic melanoma. J Transl Med 4, 50.
37. McKinney, E.F., Lyons, P.A., Carr, E.J., Hollis, J.L., Jayne, D.R., Willcocks, L.C., et al. (2010). A CD8T cell transcription signature predicts prognosis in autoimmune disease. Nat Med 16, 586-591, 581p following 591.
38. Nambiar, P.R., Gupta, R.R., and Misra, V. (2010). An "Omics" based survey of human colon cancer. Mutat Res 693, 3-18.
39. Old, L.J. (2008). Cancer vaccines: an overview. Cancer Immun 8(Suppl 1), 1.
40. Panelli, M.C., Stashower, M.E., Slade, H.B., Smith, K., Norwood, C., Abati, A., et al. (2007). Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection. Genome Biol 8, R8.
41. Pang, T., Daulaire, N., Keusch, G., Leke, R., Piot, P., Reddy, S., et al. (2010). The new age of global health governance holds promise. Nat Med 16, 1181.
42. Pankratz, V.S., Vierkant, R.A., O'Byrne, M.M., Ovsyannikova, I.G., and Poland,G.A. (2010). Associations between SNPs in candidate immune-relevant genes and rubella antibody levels: a multigenic assessment. BMC Immunol 11, 48.
43. Park, K.H., Gad, E., Goodell, V., Dang, Y., Wild, T., Higgins, D., et al. (2008). Insulin-like growth factor-binding protein-2 is a target for the immunomodulation of breast cancer. Cancer Res 68, 8400-8409.
44. Parkin, D.M., Bray, F.I., and Devesa, S.S. (2001). Cancer burden in the year 2000. The global picture. Eur J Cancer 37(Suppl 8), S4-S66.
45. Poland, G.A., Ovsyannikova, I.G., and Jacobson, R.M. (2008). Personalized vaccines: the emerging field of vaccinomics. Expert Opin Biol Ther 8, 1659-1667.
46. Pos, Z., Selleri, S., Spivey, T.L.,Wang, J.K., Liu, H.,Worschech, A., et al. (2010). Genomic scale analysis of racial impact on response to IFN-alpha. Proc Natl Acad Sci USA 107, 803-808.
47. Qiu, J., Madoz-Gurpide, J., Misek, D.E., Kuick, R., Brenner, D.E., Michailidis, G., et al. (2004). Development of natural protein microarrays for diagnosing cancer based on an antibody response to tumor antigens. J Proteome Res 3, 261-267. (Pubitemid 38500993)
48. Rammensee, H., Bachmann, J., Emmerich, N.P., Bachor, O.A., and Stevanovic, S. (1999). SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50, 213-219. (Pubitemid 30099526)
49. Reche, P.A., Glutting, J.P., and Reinherz, E.L. (2002). Prediction of MHC class I binding peptides using profile motifs. Hum Immunol 63, 701-709. (Pubitemid 34983301)
50. Reyal, F., van Vliet, M.H., Armstrong, N.J., Horlings, H.M., de Visser, K.E., Kok, M., et al. (2008). A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the proliferation, immune response and RNA splicing modules in breast cancer. Breast Cancer Res 10, R93.
51. Roepman, P., Jassem, J., Smit, E..F, Muley, T., Niklinski, J., van de Velde, T., et al. (2009). An immune response enriched 72- gene prognostic profile for early-stage non-small-cell lung cancer. Clin Cancer Res 15, 284-290.
52. Sahin, U., Tureci, O., Schmitt, H., Cochlovius, B., Johannes, T., Schmits, R., et al. (1995). Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 92, 11810-11813. (Pubitemid 26014201)
53. Salazar, L.G., Fikes, J., Southwood, S., Ishioka, G., Knutson, K.L., Gooley, T.A., et al. (2003). Immunization of cancer patients with HER-2/neu-derived peptides demonstrating high-affinity binding to multiple class II alleles. Clin Cancer Res 9, 5559-5565. (Pubitemid 37499475)
54. Salazar, L.G., Goodell, V., O'Meara, M., Knutson, K.L., Dang, Y., Dela Rosa, C., et al. (2009). Persistent immunity and survival after immunization with a HER-2/neu (HER2) vaccine. J Clin Oncol 27(Suppl):abstr 3010.
55. Sarwal, M., Chua, M.S., Kambham, N., Hsieh, S.C., Satterwhite, T., Masek, M., et al. (2003). Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med 349, 125-138. (Pubitemid 36818782)
56. Sette, A., Vitiello, A., Reherman, B., Fowler, P., Nayersina, R., Kast, W.M., et al. (1994). The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol 153, 5586-5592. (Pubitemid 24377694)
57. Singh, H., and Raghava, G.P. (2001). ProPred: prediction of HLA-DR binding sites. Bioinformatics 17, 1236-1237. (Pubitemid 33735355)
58. Sioud, M., and Hansen, M.H. (2001). Profiling the immune response in patients with breast cancer by phage-displayed cDNA libraries. Eur J Immunol 31, 716-725. (Pubitemid 32237107)
59. Soen, Y., Chen, D.S., Kraft, D.L., Davis, M.M., and Brown, P.O. (2003). Detection and characterization of cellular immune responses using peptide-MHC microarrays. PLoS Biol 1, E65.
60. Staaf, J., Ringner, M., Vallon-Christersson, J., Jonsson, G., Bendahl, P.O., Holm, K., et al. (2010). Identification of subtypes in human epidermal growth factor receptor 2-positive breast cancer reveals a gene signature prognostic of outcome. J Clin Oncol 28, 1813-1820.
61. Teschendorff, A.E., Miremadi, A., Pinder, S.E., Ellis, I.O., and Caldas, C. (2007). An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol 8, R157.
62. Ugurel, S., Schrama, D., Keller, G., Schadendorf, D., Brocker, E.B., Houben, R., et al. (2008). Impact of the CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving immunotherapy. Cancer Immunol Immunother 57, 685-691. (Pubitemid 351641030)
63. Wang, E., Miller, L.D., Ohnmacht, G.A., Mocellin, S., Perez-Diez, A., Petersen, D., et al. (2002). Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res 62, 3581-3586. (Pubitemid 34728828)
64. Wang, E., Worschech, A., and Marincola, F.M. (2008). The immunologic constant of rejection. Trends Immunol 29, 256-262.
65. Wang, X., Yu, J., Sreekumar, A., Varambally, S., Shen, R., Giacherio, D., et al. (2005). Autoantibody signatures in prostate cancer. N Engl J Med 353, 1224-1235. (Pubitemid 41345944)
66. Weng, W.K., and Levy, R (2003). Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21, 3940-3947. (Pubitemid 46606207)
67. Wierecky, J., Muller, M.R., Wirths, S., Halder-Oehler, E., Dorfel, D., Schmidt, S.M., et al. (2006). Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res 66, 5910-5918. (Pubitemid 43927146)
68. Worschech, A., Kmieciak, M., Knutson, K.L., Bear, H.D., Szalay, A.A., Wang, E., et al. (2008). Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumors. Cancer Res 68, 2436-2446. (Pubitemid 351521819)
69. Yang, R., and Roden, R. (2003). Genetic polymorphism and tumor immunotherapy. Curr Pharmacogenomics 1, 37-57.
70. Zenewicz, L.A., Abraham, C., Flavell, R.A., and Cho, J.H. (2010). Unraveling the genetics of autoimmunity. Cell 140, 791-797.
71. Zhong, L., Hidalgo, G.E., Stromberg, A.J., Khattar, N.H., Jett, J.R., Hirschowitz, E.A. (2005). Using protein microarray as a diagnostic assay for non-small cell lung cancer. Am J Respir Crit Care Med 172, 1308-1314. (Pubitemid 43076570)